219 related articles for article (PubMed ID: 28751103)
21. [Prevalence and initial management of overactive bladder in France: A cross-sectional study].
Cornu JN; Amarenco G; Bruyere F; Chartier-Kastler E; Fatton B; Grise P; Haab F; Bourouina R
Prog Urol; 2016 Jun; 26(7):415-24. PubMed ID: 27108102
[TBL] [Abstract][Full Text] [Related]
22. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
[TBL] [Abstract][Full Text] [Related]
23. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).
Matza LS; Thompson CL; Krasnow J; Brewster-Jordan J; Zyczynski T; Coyne KS
Neurourol Urodyn; 2005; 24(3):215-25. PubMed ID: 15747340
[TBL] [Abstract][Full Text] [Related]
24. Correlation between psychological stress levels and the severity of overactive bladder symptoms.
Lai H; Gardner V; Vetter J; Andriole GL
BMC Urol; 2015 Mar; 15():14. PubMed ID: 25887525
[TBL] [Abstract][Full Text] [Related]
25. Association between metabolic syndrome and overactive bladder: a case-control study.
Saratlija Novakovic Z; Tesija RA; Puljak L
Scand J Urol; 2017 Dec; 51(6):470-473. PubMed ID: 28748747
[TBL] [Abstract][Full Text] [Related]
26. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
27. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of overactive bladder symptoms and their impact on health-related quality of life of medical and dentistry students: a multicenter cross-sectional study.
Shawahna R; Hijaz H; Jallad K; Abushamma M; Sawafta M
BMC Urol; 2021 Oct; 21(1):142. PubMed ID: 34625087
[TBL] [Abstract][Full Text] [Related]
29. Bladder symptoms assessed with overactive bladder questionnaire in Parkinson's disease.
Iacovelli E; Gilio F; Meco G; Fattapposta F; Vanacore N; Brusa L; Giacomelli E; Gabriele M; Rubino A; Locuratolo N; Iani C; Pichiorri F; Colosimo C; Carbone A; Palleschi G; Inghilleri M
Mov Disord; 2010 Jul; 25(9):1203-9. PubMed ID: 20310046
[TBL] [Abstract][Full Text] [Related]
30. Overactive bladder and autonomic dysfunction: Lower urinary tract symptoms in females with postural tachycardia syndrome.
Kaufman MR; Chang-Kit L; Raj SR; Black BK; Milam DF; Reynolds WS; Biaggioni I; Robertson D; Dmochowski RR
Neurourol Urodyn; 2017 Mar; 36(3):610-613. PubMed ID: 26859225
[TBL] [Abstract][Full Text] [Related]
31. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder.
Coyne KS; Matza LS; Kopp Z; Abrams P
Eur Urol; 2006 Jun; 49(6):1079-86. PubMed ID: 16460875
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
33. What is the real burden of the overactive bladder? Results from a national prevalence study.
Santander J; Plata M; Zuluaga L; Azuero J; Daza F; Trujillo CG; Caicedo JI; Rondón M
Neurourol Urodyn; 2022 Apr; 41(4):926-934. PubMed ID: 35233807
[TBL] [Abstract][Full Text] [Related]
34. Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder.
Barsdorf AI; Carlsson M; Bushmakin AG; Quinn S; Cappelleri JC; Pleil A
Int Urogynecol J; 2017 Dec; 28(12):1857-1863. PubMed ID: 28378111
[TBL] [Abstract][Full Text] [Related]
35. Characterization of symptom bother and health-related quality of life in Japanese female patients with overactive bladder.
Gotoh M; Kobayashi T; Sogabe K
Neurourol Urodyn; 2015 Nov; 34(8):730-5. PubMed ID: 25212503
[TBL] [Abstract][Full Text] [Related]
36. Relationship between overactive bladder and irritable bowel syndrome: a large-scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria.
Matsumoto S; Hashizume K; Wada N; Hori J; Tamaki G; Kita M; Iwata T; Kakizaki H
BJU Int; 2013 Apr; 111(4):647-52. PubMed ID: 23106867
[TBL] [Abstract][Full Text] [Related]
37. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China.
Wang Y; Xu K; Hu H; Zhang X; Wang X; Na Y; Kang X
Neurourol Urodyn; 2011 Nov; 30(8):1448-55. PubMed ID: 21826714
[TBL] [Abstract][Full Text] [Related]
38. Validation of a 3-item OAB awareness tool.
Coyne KS; Margolis MK; Bavendam T; Roberts R; Elinoff V
Int J Clin Pract; 2011 Feb; 65(2):219-24. PubMed ID: 21235701
[TBL] [Abstract][Full Text] [Related]
39. Patient-reported outcomes with the β
Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
[TBL] [Abstract][Full Text] [Related]
40. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.
Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D
BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
